Loading...
•
Sep 30, 2020
LivaNova Q3 2020 Earnings Report
Reported a decrease in worldwide sales and a diluted loss per share, but showed sequential improvement in all business segments driven by U.S. Epilepsy and Advanced Circulatory Support (ACS).
Key Takeaways
LivaNova reported a decrease in worldwide sales by 10.6% and a diluted loss per share of $0.30 for Q3 2020. However, the company saw sequential improvement in all business segments, led by U.S. Epilepsy and Advanced Circulatory Support (ACS).
Worldwide sales decreased by 10.6% on a reported basis and 11.2% on a constant-currency basis compared to the same quarter of the previous year.
GAAP diluted loss per share from continuing operations was $0.30.
Adjusted diluted earnings per share from continuing operations was $0.38.
Sequential improvement in all business segments was led by growth drivers, U.S. Epilepsy and Advanced Circulatory Support (ACS).
Revenue by Segment
Forward Guidance
LivaNova expects full-year 2020 worldwide net sales to decline between 7 and 17 percent on a constant-currency basis. Adjusted diluted earnings per share from continuing operations for 2020 are expected to be in the range of $1.15 to $1.35. Free Cash Flow is now expected to be in the range of $10 million to $30 million for the full year.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...